| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | CFO & Secretary
2 companies
Corleen M. Roche is Chief Financial Officer at IOVA and has filed Form 4s across 2 companies. Corleen M. Roche's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $382K at current prices.
The biggest single holding is IOVA (~$254K) as Chief Financial Officer.
Corleen M. Roche has 11 Form 4 filings on record from April 2021 to August 2026, across 3 companies: Chief Financial Officer at Iovance Biotherapeutics (IOVA), 2025–2026; CFO at CG Oncology (CGON), 2024–2025; Chief Financial Officer at Immunome (IMNM), 2021–2023.
The 13 reported transactions were 10 option or other derivative awards, 1 option exercise, 1 tax withholding and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $38K and no sales.
The only open-market purchase was 2,000 shares of CGON at an average $19.00 on January 29, 2024, about $38K. Twelve months later CGON was down 18%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 29, 2024 | CGON Cg Oncology, Inc. | CFO & Secretary | Buy | 2,000 | $19.00 | $38,000.00 | New | +17.1% | -18.1% |